JP Patent

JP6653702B2 — 血漿カリクレイン阻害剤としてのｎ−（（ヘタ）アリールメチル）−ヘテロアリール−カルボキサミド化合物

Assigned to カルビスタ・ファーマシューティカルズ・リミテッド · Expires 2020-02-26 · 6y expired

What this patent protects

Patent listed against Ekterly.

Drugs covered by this patent

Patent Metadata

Patent number
JP6653702B2
Jurisdiction
JP
Classification
—
Expires
2020-02-26
Drug substance claim
No
Drug product claim
No
Assignee
カルビスタ・ファーマシューティカルズ・リミテッド
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.